Enhancing Health System Initiatives:
Utilizing Clinical Advances to Optimize the Diagnosis and Treatment of Prostate Cancer
Supported by educational grants from Astellas and Medivation, Inc. a Pfizer company, AstraZeneca, and Genomic Health.
The management of patients with castration-resistant prostate cancer (CRPC) has undergone enormous changes in the past 15 years. We now enjoy the benefit of 7 agents (plus Radium-223) to treat metastatic CRPC (mCRPC). Moreover, we also recognize a new clinical diagnosis, nonmetastatc CRPC (nmCRPC), which also appears to benefit from androgen receptor antagonist treatment to delay the time to metastatic disease. This interactive video activity features a presentation by an expert in prostate cancer research, providing a current overview of mCRPC and nmCRPC, including practical implications of life-prolonging therapies for mCRPC, and emerging therapeutic strategies for treating for both nmCRPC and mCRPC
The goal of this program is for academic and community urologists, radiation and medical oncologists, oncologic surgeons, residents, fellows, nurse practitioners, physician assistants, nurses, and other allied healthcare professionals interested in the treatment and management of prostate cancer to better understand the context of both nm and mCRPC and the use of the respective therapies for these disease state.
This educational initiative is intended for academic and community urologists, radiation and medical oncologists, oncologic surgeons, residents, fellows, nurse practitioners, physician assistants, nurses, and other allied healthcare professionals interested in the treatment and management of prostate cancer. No prerequisites required.
After completing this activity, participants will demonstrate the ability to:
- DEFINE nonmetastatic CRPC in the context of the Clinical States Model of prostate cancer.
- EVALUATE the clinical implications of current and emerging androgen receptor antagonist therapy for nmCRPC based on clinical trial data.
- ASSESS the practical implications of currently available therapies for mCRPC for appropriate treatment sequencing based on patient-specific factors.
In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) and the American Academy of PAs (AAPA), to provide continuing education for the healthcare team.
Credit Designation Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 interprofessional Continuing Education (IPCE) credits for learning and change.
The estimated time to complete this activity: 30 minutes.
Release date: October 10, 2018. Expiration date: October 10, 2019.
Ross E. Krasnow, MD, MPH
MedStar Washington Hospital Center
Michael A. Carducci, MD
Prostate Cancer Research Associate Cancer Center Director
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dr Carducci reports serving as a consultant for AbbVie Inc, Astellas Pharma US Inc, Churchill Pharmaceuticals LLC, F. Hoffmann-La Roche Ltd, and Pfizer Inc.
No other faculty members have indicated that they have any financial interests or relationships with a commercial entity.
The following is an archived symposium activity designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited preassessment, the archive activity, and a CE postassessment and evaluation. All 3 sections must be completed to receive CE credit. A certificate of participation will be available online immediately following successful completion of the activity.
Table of Contents
Castration-Resistant Prostate Cancer
Michael A. Carducci, MD, FACP
Postassessment and Evaluation